Category: Uncategorized

iPS IS POSSIBLE REVOLUTIONARY TREATMENT FOR TOUGH DISEASES. "Examples of specific preclinical applications summarized briefly in this minireview include the use of iPSCs to treat diseases of the liver, nervous system, eye, and heart and metabolic conditions such as diabetes." http://www.jbc.org/content/289/8/4585 View in LinkedIn

2011: FDA TREATS CORD BLOOD AS A BIOLOGICAL DRUG. By 2009, over 22,000 cord blood units (CBUs) were shipped for transplantation, and the majority of the inventory (600,000) are unlicensed CBUs, collected before regulations and now governed by an Investigational New Drug Application (IND) for procedures. http://lnkd.in/dsbbKjN View in LinkedIn

EXPLOSION IN PUBLICATIONS. "Stem cell publications show a Compound Annual Growth Rate (CAGR) of 7.0% from 2008 to 2012, which is more than twice as great as the 2.9% CAGR for global publication output on all topics in the same period ... received 50% more citations." http://lnkd.in/dt7Awxd View in LinkedIn

REGULATION OF CORD BLOOD TRANSPLANTS. "In the United States, the Food and Drug Administration regulates cord blood under the category of “Human Cells, Tissues, and Cellular and Tissue Based-Products.” Several states also require accreditation, including New York, New Jersey, and California." http://en.wikipedia.org/wiki/Cord_blood View in LinkedIn

"REGENERATIVE MEDICINE is a new and expanding area that aims to replace lost or damaged tissues in the human body through either cellular transplantation or endogenous repair. Adult stem cells infused into the circulation are currently leading the clinical front of regenerative medicine." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn

NO MORE EMBRYONIC ETHICAL ISSUES. "Clearly, using hiPSCs (iPS) in regenerative medicine removes the hESC-associated (embryonic stem cell) ethical issues that resulted in restricted funding of this research in the USA and other countries. It also raises the possibility of autologous transplantation." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn

iPS OR iPSC INDUCED PLURIPOTENT CELLS. "Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have promised to revolutionize regenerative medicine and therapies. Similar to embryonic stem cells, iPSCs possess pluripotency but avoid the associated ethical issues." http://lnkd.in/dJbF8sb View in LinkedIn

STEM CELLS MAY BE DERIVED FROM EMBRYOS OR ADULTS. "Since iPSCs can be derived directly from adult tissues, they not only bypass the need for embryos, but can be made in a patient-matched manner ... each individual could have their own pluripotent stem cell line." http://lnkd.in/dMsngrG View in LinkedIn

"IT WAS REVOLUTIONARY when Takahashi and Yamanaka showed in 2006 that adult mouse fibroblasts could also be sent back in time to an embryonic-like state by simply exogenously expressing powerful pluripotency transcription factors." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn

THE POWER OF INDUCED PLURIPOTENT STEM CELLS "lies in their potential ability to produce any cell in the human body" without using controversial embryonic tissues, and without rejection if autologous cells are used. http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn